MMPathIC Industry workshop 2017 – "Exploring needs; identifying solutions"
Event Information
Description
This facilitated workshop will ask participants to explore industry's key needs and challenges, and identify how MMPathIC and the other MRC funded molecular pathology nodes can support these, with actionable outputs from the workshop.
-
Who: we invite representation from industry, clinical (including pathology and lab medicine) specialities; academics and researchers (biomedical and the engineering and physical sciences); business development professionals; other stakeholders with an interest in diagnostic development. In addition to MMPathIC colleagues, we have confirmed representation from the wider molecular pathology node network and the Medical Research Council.
-
Where: Citylabs, Nelson Street, Manchester M13 9NQ
-
Why: only a diverse group of sector stakeholders will effectively deliver the translation of the UK's world leading stratified medicine discovery research to clinically tractable tests. Through this workshop, we will identify what industry needs and challenges are, and ask what the molecular pathology nodes can do to address these
Organiser Manchester Molecular Pathology Innovation Centre
Organiser of MMPathIC Industry workshop 2017 – "Exploring needs; identifying solutions"
MRC and EPSRC have funded a network of 6 molecular pathology nodes across the UK. The University of Manchester was successful in securing £2.9M from MRC/ EPSRC to establish one such node -- the Manchester Molecular Pathology Innovation Centre (MMPathIC)- this funding was supplemented by an additional £1.5M of industry and institutional commitment.
MMPathIC builds on specific strengths in Manchester’s MRC-funded translational research in inflammatory disease, (notably lupus, rheumatoid arthritis and psoriasis), and due to the significant capital investment already made by the MRC to the Stoller Biomarker Discovery Centre, capability exists to work across clinical specialities and ‘omic technologies. The MRC/ EPSRC funding will establish an infrastructure (including key staff) to build a pipeline to facilitate the translation of markers from discovery, through implementation and validation of novel pathology tests, to enable expansion of stratified medicine into clinical usage.
